[ad_1]
Tech2 news teamFebruary 05, 2021 10:38:24 am
In a pre-print article that has yet to be peer-reviewed by members of the research community, researchers from the Oxford Institute supported the UK’s decision to increase the interval between the first dose and the booster dose of the vaccine. COVID-19 Oxford-AstraZeneca, at 12 weeks. The study has not addressed concerns about the lack of vaccine efficacy data in the elderly, who are among the priority groups for vaccination in most countries, including Great Britain. The 12-week interval between doses was “the optimal approach to implementation,” according to the study.
The study states that none of the 12,408 people vaccinated with a single dose of the vaccine were hospitalized with Covid-19 22 days after immunization. The researchers assured vaccine recipients that protection begins 22 days after a single dose. From 22 days to 90 days after vaccination, a single dose of the vaccine was found to be 76 percent effective in preventing COVID-19 disease.
“The efficacy of the vaccine after a single standard dose of vaccine from day 22 to day 90 after vaccination was 76 percent, and modeled analysis indicated that protection did not decrease during this initial 3-month period.” Oxford scholars said in prepress. Efficacy was 82.4 percent when the first and the booster dose were separated by 12 or more weeks, compared to 54.9 percent when the booster dose was given within six weeks of the first dose. , according to the study.
While the European drug regulator has noted that there is insufficient data to determine how well the vaccine will work in people over 55, Britain has expressed confidence that the vaccine works in all age groups. Of the countries that vaccinate their population with the AstraZeneca vaccine, the UK has decided to vaccinate as many people as possible, as quickly as possible, extending the time between initial injections and booster injections. The main agenda behind this measure was to minimize the damage from multiple strains of COVID-19 that are currently affecting the British population.
Oxford states that the vaccine also reduced the transmission of SARS-CoV-2, with data suggesting a reduction of up to 67 percent in the risk of a positive COVID-19 smear test among participants in the British arm of the trial.
[ad_2]
